

Amendments to the Claims:

Please cancel Claim 54 without prejudice or disclaimer, and amend Claims 49, 50, 55, 72, 92 and 93 as set forth below.

1-48. Canceled

49. (Currently amended) A pharmaceutical combined preparation comprising:  
(a) pipamperone in a dose ranging between 5 and 15 mg of the active ingredient,  
and

(b) a therapeutically effective amount of a dopamine receptor agonist, where the dopamine receptor agonist is selected ~~chosen~~ from the group consisting of ~~pergolide,~~ amantadine, bromocriptine, cabergoline lisuride, ropinirole and pramipexole, ~~as a combined preparation for simultaneous use for treating Parkinson Disease.~~

50. (Currently amended) A pharmaceutical combined preparation comprising:  
(a) pipamperone in a dose ranging between 5 to 15 mg of the active ingredient,  
and

(b) pergolide in a dose ranging between 0.5 and 10 mg of the active ingredient, ~~as a combined preparation for simultaneous use for treating Parkinson Disease.~~

51-54. (Canceled)

55. (Currently amended) A pharmaceutical combined preparation comprising:  
(a) pipamperone in a dose ranging between 5 and 15 mg of the active ingredient,  
and

(b) levodopa/carbidopa in a dose ranging between 2000 mg/ 200 mg and 100 mg/

10 mg of the active ingredients,  
~~as a combined preparation for simultaneous~~ use for treating Parkinson Disease.

56-71. (Canceled)

72. (Currently amended) A pharmaceutical combined preparation comprising:  
(a) pipamperone in a dose ranging between 5 and 15 mg of the active ingredient,  
and  
(b) a therapeutically effective amount of levodopa associated with benserazide, ~~as~~  
~~a combined preparation for simultaneous~~ use for treating Parkinson Disease.

73-91. (Canceled)

92. (Currently amended) A pharmaceutical combined preparation comprising  
(a) pipamperone in a dose ranging between 5 and 15 mg of the active ingredient,  
and  
(b) levodopa/carbidopa in a dose ranging between 1500 mg/ 150 mg and 250 mg/  
25 mg of the active ingredients,  
~~as a combined preparation for simultaneous~~ use for treating Parkinson Disease.

93. (Currently amended) A pharmaceutical combined preparation comprising  
(a) pipamperone in a dose ranging between 5 and 15 mg of the active ingredient,  
and  
(b) levodopa/carbidopa in a dose of 500 mg/ 50 mg of the active ingredients, ~~as a~~  
~~combined preparation for simultaneous~~ use for treating Parkinson Disease.